Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bum Jun Kim

Showing results (21-30 of 129) with videos related to

Pageof 13
Sort By:
Sensors (Basel, Switzerland)|November 13, 2025
Advanced Signal Analysis Model for Internal Defect Mapping in Bridge Decks Using Impact-Echo Field TestingAvishkar Lamsal, Biggyan Lamsal, Bum-Jun Kim, et al.
International Journal of Molecular Sciences|March 14, 2026
Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell LinesSung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, et al.
Oncotarget|October 27, 2017
The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trialsHyun Joo Jang, Bum Jun Kim, Jung Han Kim, et al.
Oncotarget|January 20, 2017
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and reviewBum Jun Kim, Jung Han Kim, Hyeong Su Kim, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2017
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and reviewJung Han Kim, Bum Jun Kim, Hyun Joo Jang, et al.
Oncotarget|December 13, 2017
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysisJung Han Kim, Hyeong Su Kim, Bum Jun Kim, et al.
Oncotarget|December 13, 2017
The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysisBum Jun Kim, Jung Han Kim, Hyun Joo Jang, et al.
The Korean Journal of Internal Medicine|January 17, 2018
Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysisHong Deok Kim, Bum Jun Kim, Hyeong Su Kim, et al.
International Journal of Molecular Sciences|February 10, 2024
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the <i>MET</i> Gene: Doublet Treatment versus Single Agent TreatmentSung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, et al.
Journal of Cancer|October 5, 2016
Current Status and Perspective of Immunotherapy in Gastrointestinal CancersJung Hoon Kim, Bum Jun Kim, Hyeong Su Kim, et al.
Pageof 13

Showing results (21-30 of 129) with videos related to

Sort By:
Pageof 13
Sensors (Basel, Switzerland)|November 13, 2025
Advanced Signal Analysis Model for Internal Defect Mapping in Bridge Decks Using Impact-Echo Field TestingAvishkar Lamsal, Biggyan Lamsal, Bum-Jun Kim, et al.
International Journal of Molecular Sciences|March 14, 2026
Comparison of the Efficacy of 35 Anticancer Drugs According to Genomic Profiling and Biological Characteristics of 14 Gastric Cancer Cell LinesSung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, et al.
Oncotarget|October 27, 2017
The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trialsHyun Joo Jang, Bum Jun Kim, Jung Han Kim, et al.
Oncotarget|January 20, 2017
Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and reviewBum Jun Kim, Jung Han Kim, Hyeong Su Kim, et al.
Cancer Chemotherapy and Pharmacology|August 7, 2017
Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and reviewJung Han Kim, Bum Jun Kim, Hyun Joo Jang, et al.
Oncotarget|December 13, 2017
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysisJung Han Kim, Hyeong Su Kim, Bum Jun Kim, et al.
Oncotarget|December 13, 2017
The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysisBum Jun Kim, Jung Han Kim, Hyun Joo Jang, et al.
The Korean Journal of Internal Medicine|January 17, 2018
Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysisHong Deok Kim, Bum Jun Kim, Hyeong Su Kim, et al.
International Journal of Molecular Sciences|February 10, 2024
Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the <i>MET</i> Gene: Doublet Treatment versus Single Agent TreatmentSung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, et al.
Journal of Cancer|October 5, 2016
Current Status and Perspective of Immunotherapy in Gastrointestinal CancersJung Hoon Kim, Bum Jun Kim, Hyeong Su Kim, et al.
Pageof 13